Suppuration clinical trials
The registry lists 8 studies for Suppuration across more than 10 countries. 1 are recruiting or about to start. 1 of them are mainly about Suppuration (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 6 narrower conditions too, such as Hidradenitis Suppurativa: 642 studies, 138 open.
Get an email when these change. Save the Suppuration studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
MoonLake Immunotherapeutics AG (5) · Kristianstad University (1) · Peshawar Medical College (1) · Sanofi (1)
What is being tested here
Drugs under test in Suppuration studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Sonelokimab | 1 | 4 | 5 |
| Telithromycin | 0 | 1 | 1 |
| Azithromycin | 0 | 1 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
No Suppuration study is recruiting now.
Across all 8 studies, recruiting or not: 38% stop at 75 or younger and 38% at 65; 38% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. search them.
- A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis SuppurativaEnrolling by invitationNCT07007637Phase 316 countries
- An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)CompletedNCT06768671Phase 31 country
- Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis SuppurativaCompletedNCT05322473Phase 27 countries
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT06411899Phase 310 countries
- Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT06411379Phase 312 countries
- Treatment of Inflammation Around Implants With a Laser or an Ultrasonic DeviceCompletedNCT05772299Not applicable1 country
- Developing and Testing of Culturally Adapted Cognitive Behavior Therapy (CaCBT) for Pashto Speaking Pakistanis and AfghansCompletedNCT02797691Not applicable1 country
- TELI COM - Telithromycin in Children With Otitis MediaTerminatedNCT00315003Phase 313 countries